Report : Middle East Spinal Cord Stimulation Device for Chronic Pain Market Forecast to 2030 - Regional Analysis - by Product Type (Rechargeable and Non-Rechargeable), Application (Failed Back Syndrome, Complex Regional Pain Syndrome, Degenerative Disk Disease, and Others), and End User (Hospitals, Ambulatory Surgery Centers, and Others)
At 7.2% CAGR, Middle East Spinal Cord Stimulation Device for Chronic Pain Market is Projected to be Worth US$ 161.65 Million by 2030, says Business Market Insights
According to Business Market Insights' research, the Middle East spinal cord stimulation device for chronic pain market was valued at US$ 92.79 million in 2022 and is expected to reach US$ 161.65 million by 2030, registering a CAGR of 7.2% from 2022 to 2030. Surging aging population and rehabilitation and specialized centers providing effective treatment for spinal cord injuries are among the critical factors attributed to the Middle East spinal cord stimulation device for chronic pain market expansion.
In the Middle East, the aging population is significantly contributing to the demand for spinal cord stimulation devices for chronic pain. Over the past few decades, there has been a notable demographic shift in the region, characterized by a steady increase in life expectancy and declining birth rates. The demographic transition has led to a larger population of elderly individuals. According to the United Nations, the Middle East is aging at the fastest rate in the world, whereby the proportion of adults over 60 is predicted to triple by 2050. As the aging population continues to grow, so does the prevalence of chronic pain disorders. Healthcare providers in the region are increasingly recognizing the need for effective pain management solutions, further fueling the demand for these devices.
On the contrary, product recalls hamper the growth of Middle East spinal cord stimulation device for chronic pain market.
Based on product type, the Middle East spinal cord stimulation device for chronic pain market is bifurcated into rechargeable and non-rechargeable. The rechargeable segment held 72.0% share of the Middle East spinal cord stimulation device for chronic pain market in 2022, amassing US$ 66.81 million. It is projected to garner US$ 118.54 million by 2030 to expand at 7.4% CAGR during 2022-2030.
In terms of application, the Middle East spinal cord stimulation device for chronic pain market is segmented into failed back syndrome, complex regional pain syndrome, degenerative disk disease, and others. The complex regional pain syndrome segment held 40.7% share of the Middle East spinal cord stimulation device for chronic pain market in 2022, amassing US$ 37.73 million. It is estimated to garner US$ 64.94 million by 2030 to expand at 7.0% CAGR during 2022-2030.
By end user, the Middle East spinal cord stimulation device for chronic pain market is segmented into hospitals, ambulatory surgery centers (ASCS), and others. The hospitals segment held 68.0% share of Middle East spinal cord stimulation device for chronic pain market in 2022, amassing US$ 63.05 million. It is predicted to garner US$ 110.79 million by 2030 to expand at 7.3% CAGR during 2022-2030.
Based on country, the Middle East spinal cord stimulation device for chronic pain market is categorized into Saudi Arabia, Israel, the UAE, Qatar, Turkey, and the Rest of Middle East. Saudi Arabia held 28.5% share of Middle East spinal cord stimulation device for chronic pain market in 2022, amassing US$ 26.43 million. It is projected to garner US$ 47.53 million by 2030 to expand at 7.6% CAGR during 2022-2030.
Key players operating in the Middle East spinal cord stimulation device for chronic pain market are Boston Scientific Corp, Abbott Laboratories, Medtronic Plc, and Biotronik SE & Co KG, among others.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com